Table 2.
Changes in functional scales and quality of life with citalopram versus placebo treatment
| Variable | N (Placebo, Citalopram) | Placebo |
Citalopram |
End-point Difference: ANCOVA |
||||
|---|---|---|---|---|---|---|---|---|
| Baseline mean (SD) | Endpoint mean (SD) | Baseline mean (SD) | Endpoint mean (SD) | # F | df | p-value | ||
| SF-12 Mental | (73, 81) | 41.8(11.1) | 43.5 (9.8) | 39.8 (10.7) | 47.9(10.2) | 13.2 | 1,149 | 0.001 |
| SF-12 Physical | (73, 81) | 43.6 (10.6) | 43.8 (10.8) | 43.7 (10.2) | 42.9(10.3) | 0.4 | 1,149 | 0.552 |
| * SSPA | (65, 71) | 31.1 (7.4) | 30.4 (7.1) | 33.1 (5.7) | 33.7 (5.7) | 5.6 | 1,134 | 0.019 |
| * MMAA | (63, 73) | 10.0 (7.6) | 8.4 (7.1) | 7.8 (5.9) | 7.6 (6.6) | 0.1 | 1,131 | 0.735 |
| Quality of Life | (70, 70) | 56.8(22.1) | 57.5 (22.7) | 58.8(21.5) | 64.7 (24.5) | 4 | 1,135 | 0.046 |
Values represent means with standard deviations in parentheses.
#
F values with degrees of freedom (df) derived from analysis of covariance adjusting for baseline values, site and site by treatment interactions.
*
SSPA = social skills performance assessments; MMAA = total number of medication errors on the medication management ability assessment